The E2F family of transcription factors are essential for the regulation of genes required for appropriate progression through the cell cycle. Five members of the E2F family have been previously reported, namely E2F1-5. All ®ve are key elements in transcriptional regulation of essential genes, and they can be divided into two functional groups, those that induce S-phase progression when overexpressed in quiescent cells (E2Fs 1 ± 3), and those that do not (E2Fs 4 ± 5). Here, we describe the identi®cation of a novel member of this family, which we refer to as E2F-6. E2F-6 shares signi®cant homology with E2Fs 1 ± 5, especially within the DNA binding, heterodimerization and marked box domains. Unlike E2Fs 1 ± 5, E2F-6 lacks a transactivation and a pocket protein binding domain, hence, forms a unique third group within the E2F family. E2F-6 is a nuclear protein that can form heterodimers with the DP proteins (both DP-1 and DP-2) in vitro and in vivo. Our results show that the complex formed between E2F-6 and the DP proteins, possesses high DNA binding activity, displaying a preference for a TTTCCCGC E2F recognition site, which is slightly dierent to the E2F consensus site derived from the E2 promoter (TTTCGCGC). In contrast to the other members of the E2F family, ectopic expression of E2F-6 inhibits transcription from promoters possessing E2F recognition sites rather than activating transcription. In addition, overexpression of E2F-6 suppresses the transactivational eects of coexpression of E2F-1 and DP-1. The inhibitory eect of E2F-6 is dependent on its DNA binding activity and its ability to form heterodimers with the DPs. Interestingly, ectopic expression of E2F-6 leads to accumulation of cells in S-phase. Our data suggest that E2F-6 expression delays the exit from S-phase rather than inducing Sphase, which further emphasizes the functional dierence between E2F-6 and the previously known E2F family members.
Introduction
The E2F transcription factors are implicated in the cell cycle regulated transcription of several genes in mammalian cells (Slansky and Farnham, 1996) . Among the targets for E2F regulation are genes, whose products are required for DNA replication (dihydrofolate reductase, DNA polymerase-a, thymidine kinase, HsORC1, CDC6), and cell proliferation (cyclin E, cyclin A, CDC2, E2F-1, E2F-2, B-Myb, and p107) (Slansky and Farnham, 1996; Zhu et al., 1995; Schulze et al., 1995; Tommasi and Pfeifer, 1995; Botz et al., 1996; Geng et al., 1996; Ohtani et al., 1995 Ohtani et al., , 1996 Sears et al., 1997; Hateboer et al., 1998 submitted) . Consistent with their function as transcriptional regulators of essential cell cycle regulated genes, several experiments have demonstrated the important role played by the E2Fs for proper cell proliferation. For example, experiments have shown that overexpression of certain members of the E2F family is sucient to induce S-phase in serum starved cells Lukas et al., 1996) , transform immortalized murine ®broblasts (Johnson et al., 1994; Xu et al., 1995) , and participate in the immortalization of primary human keratinocytes (Mellilo et al., 1994) . Moreover, the use of dominant negative mutants suggests that E2F activity is required for entry into the S-phase of the cell cycle (Wu et al., 1996) . Finally, the E2Fs appear to be the downstream eectors in a pathway, whose members are frequently found mutated in human tumors, and which contains the D-type cyclins, CDK4/6, the INK4 kinase inhibitors, and the retinoblastoma protein, pRB (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) .
The ®ve members of the E2F family (E2F-1 to E2F-5) that have been identi®ed so far can be grouped into two subfamilies based on their structure and anity for members of the pRB family (pRB, p107 and p130) (Slansky and Farnham, 1996) . Binding of the E2Fs to either DP-1 or DP-2 is required for high anity binding of the E2Fs to DNA, E2F transcriptional activity and for binding to members of the pRB family (Slansky and Farnham, 1996) . Thus, E2F activity is believed to be a result of E2F/DP complex formation. Several dierent mechanisms have been described that regulate the activity of the E2F transcription factors including cell cycle regulated expression, binding by pRB family members, phosphorylation of DP proteins, targeted degradation by the ubiquitin-proteasome pathway, and cell cycle regulated subcellular localization (Cobrinik, 1996; Moberg et al., 1996; Slansky and Farnham, 1996; Campanero and Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996; MuÈ ller et al., 1997; Lindeman et al., 1997) . Based on results from several laboratories, we have proposed the following working model for how E2F-dependent transcription is regulated (MuÈ ller et al., 1997) : In quiescent cells that mainly contain E2F-4 and E2F-5 together with the nonphosphorylated forms of the pRB family, these E2Fs work as transcriptional repressors of E2F-dependent promoters. The phosphorylation of the pRB family members in mid-to-late G1 leads to the dissociation of E2F-4 and E2F-5, which are now prone for targeted degradation by the ubiquitin-proteasome pathway. The phosphorylation also leads to derepression of the E2F regulated promoters, including the promoters of E2F-1, E2F-2 and E2F-3. The subsequent synthesis of E2F-1, E2F-2, and E2F-3 further increases the expression of E2F target genes until in late S phase, where their activity is inactivated by a cyclin A dependent kinase.
In this manuscript we present results that add another layer of complexity to how E2F activity is regulating cell proliferation. We have identi®ed a cDNA in the EST database whose translation product has high homology to the members of the E2F family, and isolated a putative full length cDNA containing an open reading frame of 843 nucleotides (281 amino acids). Since this gene product exerts many of the features of E2F family members, including sequence homology, ability to bind DP proteins and the E2F DNA binding consensus, we have named the gene E2F-6. We show that E2F-6 inhibits transcription from E2F-dependent promoters, and when overexpressed leads to accumulation of cells in S-phase. Furthermore, we show that E2F-6 most likely inhibits progression through S-phase. We provide a model for the role of E2F-6 in regulating accurate passage through late Sphase into G 2 .
Results

Isolation of the human E2F-6 cDNA
Screening the EST database using the DNA binding domain of E2F-1, identi®ed three individual clones displaying high sequence homology to the target sequence, but dierent from the known E2F family members. All three clones were partially sequenced and found to contain identical sequences but they varied in length from 0.8 ± 2.0 kb. The clone with the 2.0 kb insert was sequenced in both orientations and found to contain an open reading frame (ORF) with high homology to the E2Fs. This clone (and the remaining two partially sequenced clones), however, did not contain a stop codon upstream of the ORF. A human cDNA library was screened by PCR producing several bands ranging in size from 0.5 ± 1.0 kb. Partial sequencing of some clones revealed the continuation of the ORF previously sequenced showing homology with the E2F family of proteins. Stop codons were found in all three reading frames upstream of a potential initiating methionine, which was in frame with the ORF encoded by the 2.0 kb insert. The putative full length cDNA (*2.2 kb) is presented together with a translation of the open reading frame of 281 amino acids ( Figure 1a) . We refer to this E2F member as E2F-6.
Alignment of E2F-6 with the ®ve previously known E2F family members revealed considerable homology particularly within the central region of the proteins. By comparison with E2Fs 1 ± 5, E2F-6 is the shortest member and is truncated at both the amino-and carboxy-termini, while the central core homology regions are maintained in E2F-6 (Figure 1b) . Further comparison between E2F-1 and E2F-6 revealed more speci®cally the conserved homology regions characteristic of this protein family (Figure 1c ). Most notably, E2F-6 lacks a transactivation domain and a pocket protein binding domain in the C-terminal region. E2F-6 also lacks a cyclin A binding domain N-terminal of the DNA binding domain. The DNA binding domain of E2F-6 displays the highest homology with the other E2F members and is compared here only with E2F-1 for simplicity ( Figure 1c ). It displays 48% identity to E2F-1 which rises to 67% similarity when conservative homologies are permitted. The leucine zipper, and more speci®cally the leucine residues, are conserved in E2F-6 while the marked box domain also shares signi®cant homology between the two proteins ( Figure 1c) .
Expression of E2F-6 in cell lines and tissues
To determine the pattern of E2F-6 mRNA expression, several cell lines were tested for the presence of the E2F-6 transcript by Northern analysis. E2F-6 mRNA expression levels were found to vary considerably among the dierent cell lines tested and two dierent sized transcripts were detected at approximately 3.0 kb and 4.0 kb indicating alternatively spliced variants exist. Human cell lines HT230, dierentiated HL60 (+TPA), NGP, U937 and IMR32 all demonstrated high levels of mRNA expression (Figure 2a ). NIH3T3 cell RNA was also included in the Northern analysis, but no speci®c signal was detected by the human E2F-6 probe. To investigate the tissue distribution of E2F-6 expression, human tissue Northern blots were probed using the E2F-6 probe (Figure 2b ). High levels of E2F-6 mRNA were observed in the testis and small intestine, reduced levels were detected in placenta, heart and spleen extracts, while no transcripts were detected in the remaining samples analysed. GAPDH controls were used to test for RNA levels.
E2F-6 associates with DP proteins
A characteristic of all previously reported E2Fs is their functional association with either of the two members of the DP family of proteins (Slansky and Farnham, 1996) . To investigate whether E2F-6 also associates with the DP proteins, we used both in vitro binding assays ( Figure 3a ) and co-immunoprecipitations with protein extracts from transfected U-2 OS cells ( Figure  3b ). Speci®c binding activity of E2F-6 was observed with in vitro translated DP-1 in in vitro binding assays, whereas no interaction could be detected between E2F-6 and in vitro translated pRB or E2F-1 (Figure 3a) . As positive controls for in vitro binding, we incubated GSTE2F-1 with in vitro translated pRB or DP-1 or GSTDP-1 with in vitro translated E2F-1. As negative controls we tested GSTDP-1 binding to in vitro translated pRB or GST alone incubated with in vitro translated DP-1 or E2F-1 (Figure 3a) . The degree of binding between E2F-6 and DP-1 was comparable to that observed between E2F-1 and DP-1.
Co-expression of E2F-6 with either DP-1 or DP-2 in U-2 OS cells showed that a high anity interaction can be formed between E2F-6 and both DP-1 and DP-2 individually in vivo. Reciprocal immunoprecipitations were utilized to con®rm this association (Figure 3b ). MYC-tagged E2F-6 or HA-tagged E2F-1 were cotransfected with HA-tagged DP-1 or -DP-2 and the protein extracts used for immunoprecipitations with either the anti-E2F-6 (N27) antibody or the anti-HAtag (12CA5) antibody. E2F-6 immunoprecipitations E2F-6 is a transcriptional inhibitor P Cartwright et al were probed for either HADP-1 or HADP-2 and, in both cases, high levels of the DP partner protein were observed associated with E2F-6. The reciprocal experiments demonstrate that immunoprecipitation of DPs can co-precipitate associated E2F-6 (Figure 3b ).
E2F-6 is a nuclear protein
Nuclear localisation of the E2F transcription factors is essential for their function in DNA binding. When overexpressed in U-2 OS cells, MYC-tagged E2F-6 was localised in the nucleus as determined by immunofluorescence using the 9E10 (a-MYC-tag) antibody (Figure 4 , upper left panel). This antibody did not detect any endogenous proteins in non-transfected cells at the concentrations used (data not shown) indicating the detected nuclear protein was in fact exogenously added E2F-6. We also tested the localisation of transfected HADP-1 or HADP-2 in these cells by immunofluorescence using the 12CA5 (a-HA tag) antibody. Alone, DP-1 is predominantly cytoplasmic (Figure 4 , upper right panel) while DP-2 shows predominantly nuclear staining (data not shown). Since we observed an interaction between DP-1 and DP-2 with E2F-6 in our DP binding For the three conserved regions in E2F-6, the identity and similarity has been determined with respect to E2F-1 both in terms of absolute numbers of amino acids and as a percentage assays, we tested the localisation of each when cotransfected with E2F-6. In the case of both DP-1 and DP-2 in the presence of E2F-6, we observed only nuclear staining suggesting the interaction mediates nuclear transport of DP-1 (Figure 4 , lower panels). Hence, we conclude that the heterodimeric complex formed by E2F-6 and DP proteins exists in the nucleus.
DNA binding complexes form between E2F-6 and the DPs
Protein extracts from transfected U-2 OS cells were used to demonstrate DNA binding activity of an E2F-6/DP complex. Two E2F consensus probes were tested. One with a sequence derived from the E2 promoter, and the other that was identi®ed by site selection (class I site) of oligonucleotides binding to pRB-and associated proteins (Chittenden et al., 1991; Ouellette et al., 1992) . Neither E2F-1, E2F-6, DP-1 or DP-2, when transfected alone displayed any detectable increase in levels of DNA binding activity to either the wt or class I E2F-site probes (data not shown). When E2F-1 or E2F-6 were co-expressed with DP-1, DNA binding activity was observed using either the wt (Figure 5a ) or class I probe (Figure 5b ). This DNA binding activity could be eciently competed by the addition of an excess of cold wt (Figure 5a ) or class I (Figure 5b ) probes, whereas an excess of a mutant probe was unable to disrupt the DNA binding complexes formed between the E2F and DP proteins (Figure 5a and b) . Similar results were also obtained when DP-2 was used instead of DP-1 (data not shown). Antibody supershifts were performed to con®rm the presence of E2Fs/DPs in the DNA binding complexes. E2F-1/DP-1 complexes were supershifted by either anti-E2F-1 (KH20) antibody or anti-DP-1 (TFD10) antibody but not by the anti-MYC tag (9E10) antibody (Figure 5a and b) . When E2F-6 and DP-1 were coexpressed the supershifts were generated by either the 9E10 or TFD10 antibodies but not by the KH20 antibody (Figure 5a and b). For control experiments, non-transfected U-2 OS cell lysates were used and supershifts were observed using KH20 and TFD10 antibodies, but not by the 9E10 antibody indicating the shifts observed for non-transfected lysates were speci®c to endogenous E2F/DP complexes. It appears from our data that the class I probe exhibits a similar binding anity for the endogenous E2F complexes as the wt E2F probe ( Figure 5 , U-2 OS lanes). In contrast, the E2F-6/DP complex displays a considerable binding preference for the class I probe (Figure 5a and b) and this DNA binding activity could not be competed by addition of excess cold wt probe (data not shown) suggesting the E2F-6/DP-1 complex possesses an enhanced speci®city for the TTTCCCGC DNA recognition sequence over the wt E2F site (TTTCGCGC) found in the E2 promoter. We were unable to determine a preference for either of the two sites for the E2F-1/DP-1 complex in these assays.
We tested the DNA binding anity of two E2F-6 mutants co-transfected with DP-2 (results were similar Immunoprecipitation with an a-E2F-1 polyclonal antibody followed by immunoblotting with 12CA5. Non-transfected U-2 OS cells were included as control E2F-6 is a transcriptional inhibitor P Cartwright et al for DP-1) to demonstrate the DNA binding function of E2F-6 was dependent on the full intact DNA binding domain in E2F-6 ( Figure 5c ). Two N-terminal deletion mutants were generated, one lacking residues 1 ± 51 and the second lacking residues 1 ± 80. In DNA binding assays only the E2F-6 81 ± 281 mutant had lost DNA binding ability whereas the 52 ± 281 mutant was comparable to wild-type E2F-6 in terms of DNA binding activity ( Figure 5c ). Both mutants were capable of DP binding (data not shown) and the expression level of each of the E2F-6 proteins was compared and found to be equivalent as judged by immunoblot analysis (Figure 5d ).
E2F-6 functions as a transcriptional inhibitor
The transcriptional activity generated by an E2F/DP complex results from the presence of a transactivation domain at the extreme C-terminal of the E2F component. Based on sequence analysis it appears that E2F-6 is de®cient in a transactivation domain at its C-terminal. We tested the ability of E2F-6 alone, or in combination with DP-1 (or DP-2, data not shown), to transactivate a luciferase reporter construct containing a 66E2F-recognition site. Figure 6a shows activation of this reporter construct by E2F-1 and superactivation by co-expression of DP-1. In contrast, no activation of this reporter was observed using extracts from cells transfected either with E2F-6 alone or when coexpressed with DP-1 (Figure 6a ). Even when E2F-6 levels were increased to over 100-fold higher levels than E2F-1, no transactivation could be detected (data not shown). We also tested the eect of increasing amounts of E2F-6 on the transactivation observed for coexpression of E2F-1 and DP-1. Expression of increasing amounts of E2F-6 blocked the activity generated by E2F-1 /DP-1. In U-2 OS cells 3 mg of E2F-6 was sucient to reduce activation levels to below those observed for E2F-1 alone, however, 3 ± 4-fold higher amounts were required to fully inactivate the E2F-1/DP-1 complex down to basal levels ( Figure  6a ), suggesting that E2F-6 is competing for DP-1 and/ or DNA binding in these assays. When E2F-6 along with the 66E2F reporter construct was introduced into U-2 OS cells, a down regulation of basal activity was observed (Figure 6a ). The down-regulation of basal activity could be more readily observed in C-33A cells where a higher basal activity of the E2F-responsive promoters exists most likely due to the absence of functional pRB (Figure 6b ). Since we observed stronger binding of an E2F-6/DP-1 complex to the class I probe in bandshifts ( Figure 5 ), we tested an E2F-luciferase reporter construct containing a class I type of E2F-DNA binding site. This type of E2F site (TTTCCCGC) is found in the human thymidine kinase promoter (Ogris et al., 1993) , hence, it was used in a reporter plasmid (TK-luciferase) for luciferase transactivation assays. Transactivation from this promoter construct was enhanced by E2F-1 and further stimulated by the addition of DP-1 (Figure 6c ). The basal activity of this reporter construct is considerably higher in C-33A cells than the 66E2F-luciferase reporter and we tested if E2F-6 also inhibited the activity of this construct. As little as 30 ng of E2F-6 expression plasmid was sucient to reduce the activity of this promoter to 50% of basal levels. Basal activity was further reduced when levels of transfected E2F-6 expression plasmid were increased. Increasing the levels of E2F-6 expression plasmid above 3 mg failed to signi®cantly further inactivate this promoter (data not shown). We also observed that 3 ± 4-fold higher levels of E2F-6 were required to inactivate the CGC-site containing reporter compared to that observed on the CCC-site reporter ( Figure 6 ) suggesting a strong preference for the CCC site.
To demonstrate suppression of transactivation by E2F-6 was dependent on the presence of the E2F sites in the promoter, two constructs were generated in the pGL3-promoter vector. These constructs contained either a 46TTTCCCGC site or a mutant 46TTTCATGC site upstream of a luciferase reporter. When transfected into C-33A cells, we observed activation of the`CCC' reporter by E2F-1 which was further stimulated by DP-1. This activity was eciently negated by E2F-6 ( Figure 7a ). As expected, the reporter containing the mutated E2F site was not speci®cally stimulated by the E2F-1/DP-1 complex, nor could it be down-regulated by E2F-6 (Figure 7b ). We thus conclude that the suppression achieved by E2F-6 is dependent on the presence of the functional E2F sites in the promoter.
Since increasing amounts of E2F-6 could counteract the activation observed for the E2F-1/DP-1 complex, and we have demonstrated a speci®c interaction between the DPs and E2F-6, it was possible that E2F-6 could compete with E2F-1 for DP protein binding which could then lead to a down regulation of the active E2F-1DP-1 complex. To test this we transfected C-33A cells with a 46CCC reporter plasmid alone, or in the presence of E2F-6 with increasing amounts of DP-1. We observed no increase in activity following the addition of up to 30-fold excess amounts of DP-1 (in comparison to E2F-6 levels, Figure 8a ). Hence, we can conclude that free DP-1 cannot restore activation to basal levels in the presence of E2F-6, indicating that sequestration of DP proteins alone does not provide a mechanism for E2F-6 suppression.
E2F-6 possesses the central core homology regions seen in E2Fs 1 ± 5. In our attempts to de®ne the suppressive mechanism of E2F-6, we compared the transactivation potential of two E2F-1 mutants. We Figure 4 E2F-6 localisation. U-2 OS cells were transfected with pCMVMYE2F-6 (upper left), pCMVHADP-1 (upper right) or pCMVMYE2F-6 and pCMVHADP-1 (lower panels). E2F-6 staining was performed using the 9E10 antibody (left panels). DP-1 staining was performed using the 12CA5 antibody (right panels)
E2F-6 is a transcriptional inhibitor P Cartwright et al tested an E2F-1 DNA binding mutant E132 which retains all other structural features of the wild type E2F-1 protein, and a mutant consisting of residues 1 ± 284 which lacks the transactivation domain and pocket protein binding domains. The E132 mutant was unable to suppress transactivation by the E2F-1/DP-1 complex nor could it suppress basal activity or transactivate when transfected into C-33A cells (Figure 8b ). The E2F-1 1 ± 284 mutant which resembles E2F-6 in its structural features, behaved in a similar but weaker manner to E2F-6 in terms of its ability to inhibit transactivation by E2F-1/DP-1, and also to suppress basal activity (Figure 8b) .
In order to test if DNA binding is required for the full inhibitory activity of E2F-6, the DNA binding mutant (E2F-6 81 ± 281) was tested. This mutant lacked residues 1 ± 80 and hence, removed the N-terminal portion of the proposed DNA binding domain. When assayed for inhibitor function this mutant displayed a 50% reduction in inhibition ability compared to the full length protein (Figure 8c ) despite it being expressed at similar levels ( Figure 5d and data not shown). This 50% reduction in inhibition could be negated by increasing the levels of DP partner proteins indicating that sequestration of DP proteins was giving rise to suppressor activity in the absence of DNA binding (data not shown). Another mutant (lacking residues 1 ± 51) contained the full DNA binding domain and this mutant possessed inhibitor activity equivalent to that exhibited by wild type E2F-6 indicating the N-terminal region is not essential for the inhibitory activity of E2F-6.
E2F-6 functions as an inhibitor of E2F-dependent transcription in the absence of intrinsic repressor activity
In our attempts to distinguish whether E2F-6 was an inhibitor of E2F-dependent transactivation or an active transcriptional repressor, we generated Ga14-E2F-6 fusion proteins. The Ga14 DNA binding domain was Figure 5 The E2F-6/DP complex binds to E2F DNA binding sites. Protein extracts from transfected and non-transfected U-2 OS cells were tested for binding to a 32 P labeled E2A site (wt) probe (a) or a class I site probe (b). E2F-1/DP-1 or E2F-6/DP-1 DNA containing complexes are indicated. Antibody supershifts were performed using KH20 (anti-E2F-1), TFD10 (anti-DP-1) or by 9E10 (anti-MYC tag) as indicated. DNA binding was competed by the addition of either the cold wt or mutant probes. In (b) the cI competitor refers to the cold class I site probe. The same mutant probe was used for both a and b. For (b) the U-2 OS lanes were exposed overnight to observe supershifts on endogenous E2F complexes whereas the E2F-1/DP-1 and E2F-6/DP-1 lanes were exposed for only 3 h. (c) DNA binding requires an intact DNA binding domain. DNA binding activity was determined for E2F-6 mutants (co-transfected with DP-2) using the class I probe. (d) Expression levels of the transfected E2F-6 constructs in U-2 OS cells were determined by Western blotting using the N27 polyclonal antibody E2F-6 is a transcriptional inhibitor P Cartwright et al fused to the N-terminal of wtE2F-6, E2F-6 (52 ± 281) or E2F-6 (81 ± 281). These constructs were transfected into C-33A cells together with a luciferase reporter plasmid containing 46Ga14 DNA binding sites in the TK promoter. This reporter displays high basal activity and thus was used to assess repressor function. We utilized Ga14-RB as a control for active repression as has been previously reported (Weintraub et al., 1995) .
As a loss-of-function repressor we used Ga14-RB (706F), a single amino acid pRB mutant which lacks active repressor function (Weintraub et al., 1995) . We included Ga14-E2F-1 as a control for transactivation of this reporter construct. In C-33A cells we observed a 4 ± 5-fold increase in activity due to Ga14-E2F-1 and a 10 ± 12-fold repression of activity by Ga14-RB ( Figure  9 ). We observed a 1 ± 2-fold reduction in basal activity by the Ga14-RB(706F) mutant and have used this level of reduction as non-speci®c inhibition on the reporter construct ( Figure 9 ). No reduction in basal activity (compared to that for the RB mutant) could be detected when wtE2F-6 or the E2F-6 mutants were transfected with this reporter constuct (Figure 9 ). From these results we can conclude that E2F-6 functions primarily as an inhibitor of E2F-dependent transcription and not as a general transcriptional repressor.
Figure 6 E2F-6 suppresses E2F-responsive promoters. (a) Sequestration of E2F-1/DP-1 transcriptional activity by E2F-6. U-2 OS cells were transfected with 1 mg of 66E2F-luciferase reporter and 30 ng of either pCMVHAE2F-1 or pCMVMYE2F-6 unless otherwise indicated (for E2F-6 only) and 10 ng of pCMVHADP-1. Titration of E2F-1/DP-1 transactivation was tested by increasing the levels of E2F-6 in the presence of constant amounts of E2F-1 and DP-1. (b) E2F-6 suppresses E2F-1/DP-1 transactivation also in C-33A cells. C-33A cells were cotransfected with 1 mg of 66E2F-luciferase reporter and the indicated pCMV constructs. 30 ng of E2F-1 or E2F-6 and 10 ng of DP-1 were used for the transfections. In experiments where E2F-1, DP-1 and E2F-6 pCMV constructs were present, E2F-6 levels were 1 mg. (c) E2F-6 inhibits transcriptional activity from the TK-luciferase reporter. C-33A cells were cotransfected with 1 mg of TK-luciferase reporter together with the indicated amounts of pCMV constructs. 30 ng of E2F-1 was used for transfections together with 10 ng of DP-1 when present. 1 mg of E2F-6 was added when present with E2F-1 and DP-1. Increasing levels of E2F-6 were used as indicated above the bars Figure 7 Inhibition by E2F-6 is E2F-site dependent. C-33A cells were transfected with pCMV (vector, 1 mg), pCMVHAE2F-1 (30 ng), pCMVHADP-1 (10 ng), pCMVMYE2F-6 (1 mg), or the indicated combinations thereof together with 1 mg of (a) wild-typè CCC' or (b) mutant`CAT' containing luciferase reporters
Overexpression of E2F-6 alters the cell cycle pro®le
Regulation of E2F-dependent transcription is believed to be essential for the orderly progression through the mammalian cell cycle, and several experiments have demonstrated that ectopic expression of an E2F family member is sucient to alter cell proliferation (Adams and Kaelin, 1996) . To test if overexpression of E2F-6 would deregulate proliferation, E2F-6 was coexpressed in U-2 OS cells with CD20, and CD20 positive cells were analysed for their cell cycle pro®le. As shown in Figure 10a , overexpression of E2F-6 leads to an increase in the fraction of cells in S-phase. Using microinjection of E2F-6 into quiescent RAT-1 fibroblasts, we show that this increase in S-phase was not a result of an induction of S-phase entry. In comparison, injection of E2F-1 caused almost all injected cells to enter S-phase within 16 h following injection ( Figure  10b ). In light of this, it is most likely that E2F-6 cannot in¯uence the rate of S-phase entry but functions later in the cell cycle most probably to delay the exit of cells from S-phase.
Discussion
Involvement of the E2F family of transcription factors in controlling progression through the mammalian cell cycle has been shown to be an integral component for precise cell proliferation. E2Fs 1 ± 5 have been well characterised and all ®ve proteins are cell cycle regulated either in terms of their transcription or nuclear translocation (Slansky et al., 1993; Sears et al., 1997; MuÈ ller et al., 1997; Lindeman et al., 1997) . They all possess transactivational potential and are capable of repressing transcription through their association with various members of the pocket protein family.
E2Fs 1 ± 3 repress transcription preferentially via pRB (Helin et al., 1992; Hiebert et al., 1992; Lees et al., 1993; Helin and Harlow, 1993; Geng et al., 1996) whereas E2Fs 4 ± 5 function in repression preferentially via p107 (Zamanian and Thangue, 1993; Zhu et al., 1993; Beijersbergen et al., 1994) or p130 (Hijmans et al., 1995; Sardet et al., 1995) . The mechanism of repression by these ®ve E2Fs is by recruitment of the pocket proteins to promoters containing E2F sites, where they actively repress transcription (Sellers et al., 1995; Bremner et al., 1995; Weintraub et al., 1995) . Here we describe the isolation and characterisation of a novel sixth member of the E2F family that has an ability to inhibit E2F-dependent transcription. We have called this member E2F-6 based on the nomenclature employed for the other members of this protein family. We isolated a putative full length cDNA containing an open reading frame of 843 nucleotides encoding a 281 amino acid protein that when expressed, migrates as a 38 kDa protein on SDS ± PAGE. We refer to this protein as E2F-6. We have shown that E2F-6 possesses many of the characteristics which allow it to be considered the sixth member of the E2F family of transcriptional regulators. At the structural level, E2F-6 displays a high degree of sequence identity with E2Fs 1 ± 5 particularly within the most highly conserved regions, namely, the DNA binding (48% identical to E2F-1), heterodimerisation and marked box domains. E2Fs 1 ± 5 are regulated throughout the cell cycle by their interactions with various associated factors and act at the transcriptional level at dierent stages of the cell cycle (Shirodkar et al., 1992; Cobrinik et al., 1993; Sardet et al., 1995) . In this respect, the individual E2F family members demonstrate speci®city in their activity and E2F-6 possesses characteristics that further diversify this family of proteins. The protein is N-and C-terminally truncated Figure 8 (a) DP-1 sequestration alone does not account for E2F-6 suppressor activity. C-33A cells were transfected with 1 mg of the`CCC' luciferase reporter alone or with pCMVMYE2F-6 (100 ng) and either 0 ng, 100 ng, 1000 ng or 3000 ng of pCMVHADP-1 as indicated. (b) E2F-6 functions similarly to a transactivationally inactive E2F-1. C-33A cells were transfected with the`CCC' reporter (1 mg) together with the indicated constructs. 30 ng pCMVHAE2F-1, 10 ng pCMVHADP-1 and 1 mg of either pCMVMYE2F-6, pCMVE2F-1 1 ± 284 or pCMVE2F-1 E132. (c) E2F-6 DNA binding is essential for optimal inhibitor activity. C-33A cells were transfected with pCMVHAE2F-1 (30 ng), pCMVHADP-1 (10 ng) and pCMVMYE2F-6 (1 mg) or mutants of pCMVMYE2F-6 (1 mg) together with the 46`CCC' luciferase reporter construct (1 mg) E2F-6 is a transcriptional inhibitor P Cartwright et al compared to E2Fs 1 ± 5 and lacks the pocket protein binding domain at the C-terminal and the N-terminal cyclin binding domain. The E2F 1 ± 5 C-terminal region also encompasses the transactivation domain which is strikingly absent from E2F-6. Accordingly, we have presented evidence in this report showing that E2F-6 cannot transactivate from promoters containing E2F recognition sites and is incapable of forming an interaction with the pocket protein, pRB. In contrast to E2Fs 1 ± 5, E2F-6 in the absence of pocket proteins has the capacity to inhibit transcription from promoters containing E2F recognition sites. We demonstrated that this inhibitory function of E2F-6 is dependent on its DNA binding activity and on an interaction with DP partner proteins. DNA binding assays indicate that the E2F-6/DP complex is capable of high anity binding to E2F DNA recognition sites. In particular, this complex displays a binding preference for a TTTCCCGC site over the E2F site identi®ed in the E2A promoter (TTTCGCGC) and the latter site cannot compete with the preferred site for binding. Our ®ndings also demonstrate that suppression of the TK promoter (containing the preferred`CCC' site) requires significantly lower levels of E2F-6 than that required for suppression of the E2F-6/DPA promoter (CGC recognition site). This correlates well with the gel retardation assays in which the E2F-6/DP complex preferentially binds to a CCC probe. Since the E2F-6/ DP complex cannot compete for DNA binding to the E2A recognition site with the E2F/DP complex, we speculate that these complexes are most likely either present in dierent phases of the cell cycle or that E2F-6/DP may be responsible for regulating an entirely Figure 9 E2F-6 does not actively repress. Ga14-E2F-6 fusion proteins were transfected into C-33A cells and assayed for repressor function on a Ga14-TK-luciferase reporter. Ga14-RB and Ga14-RB(706F) were used as controls for repression and loss of repressor function respectively. Basal activity of the reporter plasmid transfected with Ga14 alone is set at 100
Figure 10 E2F-6 overexpression leads to an accumulation of cells in S-phase. (a) U-2 OS cells were transiently transfected with pCMVCD20 (2 mg) and the indicated amount of pCMVMYE2F-6 or empty expression vector. Cells were harvested 24 h after removal of the DNA precipitate and prepared for CD20 gating and propidium iodide staining. The percentage of cells in G 0 G 1 , S and G 2 M phase is presented. (b) Expression of E2F-6 does not induce S-phase entry. Luciferase alone, or in the presence of either E2F-6 or E2F-1 was injected into the nuclei of quiescent RAT-1 ®broblasts. Cells were kept in BrdU containing medium for 16 h and the percentage of BrdU incorporating injected cells was determined. Injected cells were identi®ed by staining for luciferase dierent subset of genes previously unidenti®ed as E2F targets. These targets may not be detected in genetic screens utilizing E2Fs 1 ± 5 since E2Fs 1 ± 5 may possess an equal (if not higher) anity for the CGC site rather than a CCC site. It has been reported that the E2F/pRB complex targets a dierent set of genes to those targeted by the E2F/p107 or E2F/p130 complexes (Hurford et al., 1997) . This, however, does not preclude E2F-6 from down-regulating some of the same genes regulated by other E2F members during dierent phases of the cell cycle. For example, genes such as c-Myc (Hiebert et al., 1989) , DNA polymerase a (Pearson et al., 1991) , B-myb (Lam and Watson, 1993) , and cyclin E (Ohtani et al., 1995; Geng et al., 1996; Botz et al., 1996) all contain a`CCC' E2F site in their promoters and thus, may be targets for downregulation by E2F-6.
Overexpression of E2F-6 in asynchronous U-2 OS cells results in the accumulation of cells in S-phase. Due to the absence of a transactivation domain in E2F-6, it is unlikely that it achieves this eect through up-regulation of E2F-6 responsive genes in G1 phase. Consistent with this, E2F-6 is unable to induce quiescent cells to enter S-phase. An E2F-6-mediated increase in S-phase may arise from either delayed exit from S-phase, or an alteration in the normal progression of cells through S-phase. As has been observed for cyclinA-kinase regulation of E2F-1, the lack of disruption of an E2F/DP/DNA complex in Sphase results in either a delay or block in S-phase, possibly via the activation of essential S-phase checkpoint genes . It was also demonstrated that phosphorylation of DP-1 by E2F-bound cyclinA-kinase was essential for the dissolution of the active DNA binding E2F/DP complex in Sphase . Krek et al. (1995) , proposed that continued occupance of speci®c E2F promoter sites during S-phase was responsible for the observed S-phase block. In light of this hypothesis, E2F-6 may function as such a regulator of essential S-phase checkpoint genes. E2F-6 forms a complex with DP-1 but this complex is transcriptionally inactive. If DP-1 can only be phosphorylated through E2F-associated cyclinA-kinase activity, we would not expect the E2F-6/DP-1 complex to be dissolved via this mechanism since E2F-6 lacks a cyclinA binding domain and does not contain any consensus sites for cyclin dependent kinases. Hence, a non-DP-1 phosphorylatable, transcriptionally inactive E2F-6/DP1 DNA binding complex may exist in cells where normal S-phase progression is compromised. For example, following cellular DNA damage, expression of E2F-6 may be upregulated to inhibit E2F-dependent transcription in Sphase and therefore, delay the progression of cells through S-phase until either the damage has been repaired or the cell has been targeted for apoptosis. The E2F-6/DP complex in this sense may remain DNA-bound and generate a delay in S-phase progression until such time as the cell is ready to commit to either mechanism. Further investigation will be required to identify the signals regulating E2F-6 expression throughout the cell cycle and to identify the speci®c targets of E2F-6.
While this manuscript was being reviewed, Morkel et al. (1997) described the identi®cation of an E2F-like transcriptional repressor termed EMA (E2F-binding site modulating activity). EMA is a mouse protein which displays high homolgy to the human E2F-6 described in this report and was shown to act as an active transcriptional repressor when targeted to DNA via fusion to the DNA binding domain of Ga14. An active repression domain was mapped to the Nterminus of EMA (Morkel et al., 1997) . From data presented here we can conclude that E2F-6 and EMA may be functionally distinct since E2F-6 does not actively repress transcription and deletion of the Nterminal 50 residues has little bearing on the inhibitory function of E2F-6. The dierences observed may be accounted for by species diversity, however, further investigation is needed to determine if they possess functional equivalence in terms of transcriptional regulation.
Materials and methods
Cloning the human E2F-6 cDNA A clone with high homology to E2F-1 was identi®ed by searching the EST database (`IMAGE Consortium Clone ID 548873') and was purchased from Research Genetics, Inc. This`IMAGE Consortium (LLNL) cDNA Clone 548873' contained an insert of 2020 bp cloned into pBSK (Stratagene). To obtain the 5' end of the E2F-6 cDNA, an ML-1 cDNA library constructed in Lambda Zap Express was screened by PCR using Taq DNA polymerase (Perkin Elmer). Primers utilized for the library screening were the T7 primer as the upstream primer and an internal E2F-6 primer with the following sequence; 5'-TATGGATCCT-GAATGCTATGAATGAATGTC-3' as downstream primer. The resulting PCR products were cloned directly into the pCR TM 2.1 vector (Invitrogen) and screened for inserts by restriction digestion. Clones containing the largest inserts were selected for sequencing. These clones provided the 5' region of the E2F-6 cDNA which were subsequently cloned into pBSK clone 548873 by insertion at the SacII and BglII sites to generate a putative full length E2F-6 cDNA in pBSK. For mammalian expression experiments, E2F-6 was cloned into a modi®ed pCMVneoBam vector to introduce a MYC tag at the amino-terminus of the expressed product. For cloning into pCMVMY, full length E2F-6 was obtained by PCR using pfu DNA polymerase (Stratagene) with the following primers: upstream (5'-AATGGATCCATGAGTCAGCAGCGGC-CG-3') and downstream (5'-ATGGATCCAATTATCAC-CATGAC-3') to generate BamHI restriction sites at both ends. This construct was veri®ed by sequencing and used for all wild-type E2F-6 transactivation, band shift assays, CD20 gating analysis, microinjection and immunoblotting experiments. E2F-6 deletion mutants were constructed as follows: For E2F-6 (amino acids 52 ± 281), we used PCR to introduce a BamHI site at the 5' end. The primers used were: upstream (5'-AATGGATCCATGAGAAAAGCTC-3') with the same downstream primer as used for cloning the full length cDNA into pCMVMY. This construct resulted in an amino acid change at position 51 (V-G). This mutant lacks residues 1 ± 51 from wild-type E2F-6. To construct E2F-6 (81 ± 281), we digested the full length cDNA with BglII and BamHI to isolate a 1477 bp fragment which was cloned directly into pCMVMY. All constructs involving PCR were sequenced on both strands while others were sequenced across the cloning sites to ensure the absence of incorporated mutations during PCR or cloning: Cloning of the 46CCC and 46CAT vectors were as follows: two repeats of either the CCC (5'-AGTTTCCCGCTTAAAATCGTAGAGTTTCCCGCT-TAAAA-3') or the CAT (5'-AGTTTCATGCTTAAA-ATCGTAGAGTTTCATGCTTAAAA-3') oligonucleotides were blunt end cloned into the SmaI site of the pGL3-Promoter vector (Promega).
Cell culture and transfections
C-33A and U-2 OS cells were grown, maintained and transfected as described (MuÈ ller et al., 1997) with minor modi®cations. The DNA-calcium phosphate precipitate was left on cells for 16 h and removed by two washes with PBS and re-fed with DMEM containing 10% BCS (HyClone). Cells were harvested 24 h after removal of the DNA precipitate.
Gel retardation assays
Gel retardation assays were performed as previously described (Helin et al., 1992) . The following oligonucleotides were used as probes: E2F wt probe (5'-ATT-TAAGTTTCGCGCCCTTTCTCAA-3'), E2F class I probe (5'-ATTCAATTTTCCCGCCAAAATTGAC-3') (Ouellette et al., 1992) and E2F mut probe (5'-ATTTAAGTTTC-GATCCCTTTCTCAA-3'). Where indicated, antibodies utilized for supershift analysis included KH20 (a-E2F-1; Helin et al., 1993b) , 9E10 (a-MYC tag; Evan et al., 1985) and TFD10 (a-DPA-1; Zerfass-Thome et al., 1997).
Transactivation and repression assays
The 66E2F-luciferase and TK-luciferase reporter constructs have been reported previously (Li et al., 1994; MuÈ ller et al., 1997) . pM2, pM2-RB (Ga14-RB) and pM2-RB706F (Ga14-RB(706F)) have been described (Sadowski et al., 1992; Weintraub et al., 1995) . Ga14-E2F-1 has been decribed (Helin et al., 1993b) . The Ga14-TK-Luciferase reporter was a gift from N La Thangue. Ga14-E2F-6 constructs were generated using the same fragments of E2F-6 as used for constructing the pCMVMYE2F-6 expression plasmids. For transactivation assays, C-33A or U-2 OS cells were grown in 60 mm dishes and transfected with 1 mg of luciferase reporter plasmid, 1 mg of pCMVbGal plasmid as an internal control and the indicated amounts of the expression plasmids pCMVHAE2F-1 , pCMVHADP-1 (Helin et al., 1993b) , pCMVE2F-1 1 ± 284 (Helin et al., 1993a) , pCMVE2F-1 E132 , pCMVMYE2F-6 52 ± 281, pCMVMYE2F-6 81 ± 281, pCMVMYE2F-6 or a combination thereof. DNA levels were brought to a total of 10 mg per plate by the addition of sheared salmon sperm DNA. Transfected cells were harvested by gentle scraping into 200 ml of luciferase assay lysis buer (25 mM Glycyl glycine pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 1% Triton-X100). Lysates were transferred to Eppendorf tubes and centrifuged at 14 000 r.p.m. for 10 min at 48C. The clear supernatants were used for luciferase and b-galactosidase activity assays. For luciferase assays, 50 ml lysate was added to 50 ml of luciferase reaction buer (25 mM Glycyl glycine pH 7.8, 15 mM MgSO 4 , 4 mM EGTA, 48 mM phosphate pH 7.8, 1 mM DTT, 6 mM ATP). Luciferase activity was measured in 96-well microtitre plates using an anthos lucy I luminometer (Labtec) following the addition of 50 ml of a 10 mM luciferin solution as substrate. For b-galactosidase assays, 10 ml of cell lysate was added to 40 ml of buer Z (60 mM Na 2 HPO 4 , 10 mM KCl, 1 mM MgSO 4 , pH 7.0) in a 96-well microtitre plate. The reaction was initiated by the addition of 10 ml of ONPG substrate (4 mg/ml o-nitrophenyl-b-Dgalactopyranoside (Sigma) in 100 mM phosphate buer pH 7.0) and incubation at 378C for 15 min. To stop the reaction, 25 ml of 1 M sodium carbonate was added and the plate was read at 420 nm using an MRX microplate Reader (Dynatech Laboratories). All assays were an average of at least three experiments and all experiments were normalised to b-galactosidase expression.
Immunoprecipitation and immunoblotting
Protein extracts were prepared from transiently transfected U-2 OS cells by scraping the cells and resuspending the cell pellet in 70 ml of buer C (20 mM HEPES pH 7.9, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM PMSF, 0.5 mM DTT, 25% glycerol). After three rounds of freeze/thawing, lysates were incubated on ice for 20 min and then centrifuged at 14 000 r.p.m. for 20 min at 48C. Supernatants were assayed for total protein using the Bradford method (BioRad) according to the instructions provided. For immunoprecipitations the supernatants were diluted ®vefold to 100 ml with E1A lysis buer (ELB; 50 mM HEPES pH 7.0, 250 mM NaCl, 0.1 % NP40, 1 mM EDTA) and incubated in the presence of 5 ml of rabbit polyclonal antisera or 20 ml of monoclonal supernatant and incubated on ice for 60 min. Protein A-Sepharose (100 ml of 10% slurry in ELB) was added and the reactions incubated for a further 60 min at 48C on a gentle rotating mixer. Pellets were washed three times with ELB, resuspended in 30 ml of 16Laemmli sample buer and heated to 958C for 10 min prior to loading on a 10% polyacrylamide gel. Immunoblotting was performed according to standard methods (Harlow and Lane, 1988) . Antibodies used included the monoclonal antibodies KH20 (a-E2F-1; Helin et al., 1993b) and 12CA5 (a-HA tag for HADP-1, HADP-2, HAE2F-1; Field et al., 1988) and the polyclonal antisera N27 (a-E2F-6 this report). The ECLenhanced chemiluminescent kit (Amersham) was used for detection.
Antisera
Polyclonal anti-E2F-6 antisera was generated by Primm (Milano, Italy). Rabbits were injected with a puri®ed GSTE2F-6 fusion protein consisting of residues 81 ± 281 of E2F-6 fused to the C-terminal of GST. To generate the GSTE2F-6 fusion construct the BglII/BamHI 3' end fragment of the E2F-6 cDNA was cloned into pGEX4T-1 (Pharmacia) at the BamHI site in the polylinker. Expression and puri®cation of the GSTE2F-6 fusion protein from bacteria was essentially as described (Smith and Johnson, 1988) .
DNA sequencing and analysis
The full length E2F-6 cDNA was sequenced on both strands using the automated DNA Sequencer 725 (Vistra DNA systems) and the T7 and T3 sequencing primers. Exonuclease III digestion was used to generate deletion plasmids to enable sequencing of the entire cDNA in both directions. Analysis and manipulation of DNA sequences was performed using the DNASIS software.
Northern analysis
Total cellular RNA (20 mg) from the cell lines HT230 (colon adenocarcinoma), IMR32 (neuroblastoma), HL60 (promyeloid leukemia), U937 (histiocytic lymphoma), NGP (neuroblastoma) U-2 OS (osteosarcoma) and MCF-7 (breast carcinoma) were separated in 1.0% agarose/ formaldehyde gel and transferred to nitrocellulose. Northern blots from dierent human tissues were obtained from Clontech. After prehybridization (50% deionized formamide, 1% SDS, 56SSC, 56Denhardt's, 100 mg/ml herring sperm DNA) at 428C for 4 ± 16 h, blots were hybridized for 20 h with 32 P random prime labeled (Amersham) 450 bp BglII-ClaI E2F-6 fragment. Filters were washed twice for 30 min at room temperature with 26SSC, 1% SDS and twice for 30 min at 428C with 0.26SSC, 0.1% SDS and exposed to X-ray autoradiography.
In vitro binding assay
Plasmids encoding GSTE2F-1 and GSTDP-1 have been described previously (Helin et al., 1993a,b) . GSTE2F-6 is described in this report. Plasmids for in vitro translations included pBSKHAE2F-1 , pBSKHADP-1 (Helin et al., 1993b) and pSG5RB (Qin et al., 1992) . The binding assay was performed as follows: GST-fusion protein (1 mg) was incubated with in vitro translated products DP-1 (3 ml), E2F-1 (3 ml) or pRB (6 ml) in ELB in a total of 100 ml for 2 h at 48C. Glutathione Sepharose (Pharmacia) was added (20 ml from a 50% slurry) and the reaction continued for 30 min with gentle rotation. The Sepharose was pelleted, washed three times with E1A lysis buer, resuspended in 26Laemmli sample buer and heated at 958C for 10 min prior to loading on an 8% polyaerylamide gel. After drying, the gel was exposed to X-ray ®lm.
FACS analysis
For FACS analysis, U-2 OS cells were were grown in a 100 mm dish and transfected with 2 mg pCMVCD20 (Zhu et al., 1993) and the indicated amount of pCMVMYE2F-6 expression vector. Transfected cells were washed by two washes with PBS and then detached from the dish using 1 ml of 5 mM EDTA in PBS for 5 min. The cells were transferred to an Eppendorf tube and washed by pelleting them at 3000 r.p.m. for 2 min and resuspending them in 1 ml of fresh, cold PBS. The cells were pelleted again and resuspended in 20 ml CD20 staining solution (15 ml cold PBS+5 ml FITC-labeled anti-CD20 antibody (Becton Dickinson)). After 30 min of incubation on ice with occasional agitation, the cells were washed by two washes with 1 ml of cold PBS. After the second wash the pelleted cells were carefully resuspended in 100 ml of cold PBS and then ®xed by dropwise addition of ice cold 70% methanol in PBS. The ®xation was stopped after 5 min of incubation on ice by pelleting the cells. The pellet was resuspended in 500 ml PBS containing 1% FCS. The cells were pelleted again and resuspended in 500 ml of PI-buer (10 mM TrisHCl pH 7.0, 5 mM MgCl 2 , 50 mg/ml propidium iodide (Sigma), 100 mg/ml RNase A). After 60 min of incubation at 378C the samples were analysed using a Becton Dickinson FACScan. The data were analysed using the CellQuest TM (Becton Dickinson, June 1994) and ModFit LT (Verity) software.
Microinjection
For DNA-microinjection experiments, RAT-1 cells were grown on glass-coverslips to 30% con¯uency and then incubated in DMEM without serum for 48 h. At the time of microinjection the cells had reached 60 ± 80% conuency. Microinjections were performed using a Zeiss automated microinjection device connected to an Eppendorf injector with the following settings: time of injection 0.0 s, pressure 50 ± 150 hPa, angle 458 speed 20. Glass capillaries (GC120TF-10, Clark Electromedical instruments) were pulled using the P-87 puller from Sutter Instruments. The injection time per coverslip did not exceed 30 min. The injection medium was DMEM without serum. Injected DNA was diluted in ®lter sterilized PBS to a ®nal concentration of 100 ng/ml for pCMV-luciferase (microinjection marker) or 10 ng/ml for pCMV-E2F. After microinjection the cells were allowed to recover for 3 h, then BrdU (100 mM) was added to all dishes at the same time. Cells were ®xed for immunostaining 16 h after the addition of BrdU. Fixation was done in methanol/acetone 1 : 1 (7208C, 5 min). The coverslips were dried and exposed to 1.5 N HCl for 30 min (for BrdU-detection), washed extensively in distilled water and redried. The injected cells were identi®ed by luciferase staining using an anti-luciferase polyclonal rabbit antibody (Promega E4191) followed by a goat-anti-rabbit-IgG coupled to Cy-3 (Jackson Laboratories). BrdU was detected using the FITC-conjugated anti-BrdU antibody from Becton Dickinson. The DNA was stained with DAPI. The experiments were repeated three times with essentially identical results.
Immuno¯uorescence U-2 OS cells were grown to 50% con¯uency in 60 mm dishes containing coverslips and transfected with pCMVMYE2F-6, pCMVHADP-1 or both. Twenty-four hours after removal of the DNA precipitate cells were washed and ®xed as described (MuÈ ller et al., 1997) . 9E10 or 12CA5 were used as the primary antibody (diluted 1 : 5 in DMEM+10% serum) for 1 h at room temperature. After ®ve washes with PBS coverslips were incubated with secondary antibody (Cy 3-conjugated anti mouse, diluted 1 : 500 in DMEM+10% serum) for 1 h at room temperature in the dark. Coverslips were washed ®ve times in PBS and once in PBS containing DAPI for nuclear staining and then allowed to dry before mounting. Slides were analysed with a¯uorescence microscope (Aristoplan; Leitz) and images obtained using a JVC KYF55BE video camera and visualized using the Image Grabber 24 1.2 software (Neotech).
